(Q38281750)

1 September 2017

1 reference

title

The war against heart failure: the Lancet lecture (English)

1 reference

1 September 2017

0 references

1

Eugene Braunwald

1 reference

1 September 2017

language of work or name

English

0 references

publication date

16 November 2014

1 reference

1 September 2017

number of pages

13

1 reference

inferred from page(s)

published in

The Lancet

1 reference

1 September 2017

volume

385

1 reference

1 September 2017

issue

9970

1 reference

1 September 2017

page(s)

812-824

1 reference

Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Executive Summary: Heart Disease and Stroke Statistics—2014 Update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Epidemiology of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The Global Burden of Ischemic Heart Disease in 1990 and 2010: The Global Burden of Disease 2010 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Aging of the United States population: impact on heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Angiotensin-neprilysin inhibition versus enalapril in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Acute heart failure syndromes: current state and framework for future research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The national heart failure audit for England and Wales 2008-2009.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Heart failure epidemiology: European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cardiovascular risk and events in 17 low-, middle-, and high-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Calcium movements inside the sarcoplasmic reticulum of cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Calcium cycling proteins and heart failure: mechanisms and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Dysfunctional ryanodine receptors in the heart: new insights into complex cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Mechanisms of altered Ca²⁺ handling in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Outcome in phospholamban R14del carriers: results of a large multicentre cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

S100A1 in human heart failure: lack of recovery following left ventricular assist device support

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Role of RyR2 phosphorylation at S2814 during heart failure progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Glybera and the future of gene therapy in the European Union

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Gene therapy using adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Heart failure gene therapy: the path to clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Targeting phospholamban by gene transfer in human heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Targeting S100A1 in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Prospects for gene transfer for clinical heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

microRNAs in cardiovascular diseases: current knowledge and the road ahead.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

MicroRNAs in heart failure: is the picture becoming less miRky?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Non-coding RNAs in cardiac remodeling and heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Control of stress-dependent cardiac growth and gene expression by a microRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Treatment of HCV infection by targeting microRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

MicroRNA-133 controls cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Inhibition of miR-25 improves cardiac contractility in the failing heart.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Comparison of different miR-21 inhibitor chemistries in a cardiac disease model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Circulating microRNAs as stable blood-based markers for cancer detection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

MiR423-5p as a circulating biomarker for heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cardiac fibroblasts are predisposed to convert into myocyte phenotype: specific effect of transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Bone marrow cells regenerate infarcted myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The advancing field of cell-based therapy: insights and lessons from clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Embryonic stem cell trials for macular degeneration: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Target populations for first-in-human embryonic stem cell research in spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Tumor-free iPS stem cells for heart cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Small molecules enable cardiac reprogramming of mouse fibroblasts with a single factor, Oct4.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Paracrine mechanisms in adult stem cell signaling and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Regenerative therapy for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Stem cell treatment for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cardiopoietic Stem Cell Therapy in Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Cardiomyocyte transplantation improves heart function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The post-natal heart contains a myocardial stem cell population.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Adult cardiac stem cells are multipotent and support myocardial regeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The adult human heart as a source for stem cells: repair strategies with embryonic-like progenitor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Isolation and expansion of adult cardiac stem cells from human and murine heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Rejuvenation of human cardiac progenitor cells with Pim-1 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Bridging to cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Long-term use of a left ventricular assist device for end-stage heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Sixth INTERMACS annual report: a 10,000-patient database.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Trends in the use and outcomes of ventricular assist devices among medicare beneficiaries, 2006 through 2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Challenges in long-term mechanical circulatory support and biological replacement of the failing heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Unexpected abrupt increase in left ventricular assist device thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Improved Left Ventricular Function After Chronic Left Ventricular Unloading

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Molecular changes after left ventricular assist device support for heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Molecular- and organelle-based predictive paradigm underlying recovery by left ventricular assist device support

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Prolonged bed rest in the treatment of the dilated heart.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Myocardial recovery and the failing heart: myth, magic, or molecular target?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Left ventricular assist system as a bridge to myocardial recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Left ventricular assist device and drug therapy for the reversal of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Long-term outcomes of patients bridged to recovery versus patients bridged to transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Pre-explant stability of unloading-promoted cardiac improvement predicts outcome after weaning from ventricular assist devices.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Treatment strategies for myocardial recovery in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Int

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961889-4

7 January 2021

10.1016/S0140-6736(14)61889-4

Identifiers

DOI

1 reference

1 September 2017

1 reference